Dr. McNabb is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4150 clement
San Francisco, CA 94121
Education & Training
University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 2010 - 2013
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2007 - 2010
Drexel University College of MedicineClass of 2007
Certifications & Licensure
CA State Medical License 2009 - 2025- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV Start of enrollment: 2016 Apr 19
- Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis Start of enrollment: 2016 Jul 29
- Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant Start of enrollment: 2016 Jul 27
Publications & Presentations
PubMed
- 19 citationsComparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT Extension I trialsTiffany Y. Kim, Douglas C. Bauer, Brian McNabb, Anne L. Schafer, Felicia Cosman
Journal of Bone and Mineral Research. 2019-05-01 - 67 citationsEfficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.Rafael Esteban, Juan A. Pineda, Jose Luis Calleja, Marta Casado, Manuel J. Rodriguez
Gastroenterology. 2018-10-01 - 47 citationsSofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.Kosh Agarwal, Lluis Castells, Beat Müllhaupt, William Rosenberg, Brian McNabb
Journal of Hepatology. 2018-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
